Effects of 17β-estradiol and estrogen receptor antagonists on the proliferation of gastric cancer cell lines

Myung Jin Kim, Sung Il Cho, Kun Ok Lee, Hyung Joon Han, Taejin Song, Seong-Heum Park

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: The aims of this study were as follow: 1) to describe the expression status of estrogen receptor-α and-β mRNAs in five gastric carcinoma cell lines; 2) to evaluate in vitro the effects of 17β-estradiol and estrogen receptor antagonists on the proliferation of the cell lines. Materials and Methods: Detection of estrogen receptor-α and estrogen receptor-β mRNA in five human gastric cancer cell lines (AGS, KATO III, MKN28, MKN45 and MKN74) was made by the reverse transcription-polymerase chain reaction system. To evaluate the effect of 17β-estradiol and estrogen receptor antagonists on the proliferation of gastric cancer cell line, the cell lines which expressed both estrogen receptors were chosen and treated with 17β-estradiol and estrogen receptor antagonists (methyl-piperidino-pyrazole and pyrazolo [1,5-a] pyrimidine). Cell proliferation was assessed with the methylthiazol tetrazolium test. Results: Estrogen receptor-α and estrogen receptor-β mRNAs were expressed in three (KATO III, MKN28 and MKN45) and all of the five gastric cancer cell lines, respectively. At higher concentrations, 17β-estradiol inhibited cell growth of MKN28, MKN45 and KATO III cell lines. Neither estrogen receptor-α nor estrogen receptor-β antagonist blocked the anti-proliferative effect of 17β-estradiol. Conclusions: Our results indicate that estrogen receptor-β mRNAs are preferentially expressed in gastric cancers and also imply that hormone therapy rather than estrogen receptor blockers may be a useful strategy for the treatment of estrogen receptor-β positive gastric cancer. Its therapeutic significance in gastric cancer are, however, limited until more evidence of the roles of estrogen receptors in the gastric cancer are accumulated.

Original languageEnglish
Pages (from-to)172-178
Number of pages7
JournalJournal of Gastric Cancer
Volume13
Issue number3
DOIs
Publication statusPublished - 2013 Oct 10

Fingerprint

Estrogen Receptors
Stomach Neoplasms
Cell Line
Messenger RNA
Estradiol
Estrogen Receptor Antagonists
Reverse Transcription
Stomach
Cell Proliferation
Hormones
Carcinoma
Polymerase Chain Reaction
Therapeutics

Keywords

  • Cell line
  • Estrogen
  • Estrogens
  • Receptors
  • Stomach neoplasms

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Cancer Research

Cite this

Effects of 17β-estradiol and estrogen receptor antagonists on the proliferation of gastric cancer cell lines. / Kim, Myung Jin; Cho, Sung Il; Lee, Kun Ok; Han, Hyung Joon; Song, Taejin; Park, Seong-Heum.

In: Journal of Gastric Cancer, Vol. 13, No. 3, 10.10.2013, p. 172-178.

Research output: Contribution to journalArticle

@article{389fcda864b14f60a1990ea4c1809fd9,
title = "Effects of 17β-estradiol and estrogen receptor antagonists on the proliferation of gastric cancer cell lines",
abstract = "Purpose: The aims of this study were as follow: 1) to describe the expression status of estrogen receptor-α and-β mRNAs in five gastric carcinoma cell lines; 2) to evaluate in vitro the effects of 17β-estradiol and estrogen receptor antagonists on the proliferation of the cell lines. Materials and Methods: Detection of estrogen receptor-α and estrogen receptor-β mRNA in five human gastric cancer cell lines (AGS, KATO III, MKN28, MKN45 and MKN74) was made by the reverse transcription-polymerase chain reaction system. To evaluate the effect of 17β-estradiol and estrogen receptor antagonists on the proliferation of gastric cancer cell line, the cell lines which expressed both estrogen receptors were chosen and treated with 17β-estradiol and estrogen receptor antagonists (methyl-piperidino-pyrazole and pyrazolo [1,5-a] pyrimidine). Cell proliferation was assessed with the methylthiazol tetrazolium test. Results: Estrogen receptor-α and estrogen receptor-β mRNAs were expressed in three (KATO III, MKN28 and MKN45) and all of the five gastric cancer cell lines, respectively. At higher concentrations, 17β-estradiol inhibited cell growth of MKN28, MKN45 and KATO III cell lines. Neither estrogen receptor-α nor estrogen receptor-β antagonist blocked the anti-proliferative effect of 17β-estradiol. Conclusions: Our results indicate that estrogen receptor-β mRNAs are preferentially expressed in gastric cancers and also imply that hormone therapy rather than estrogen receptor blockers may be a useful strategy for the treatment of estrogen receptor-β positive gastric cancer. Its therapeutic significance in gastric cancer are, however, limited until more evidence of the roles of estrogen receptors in the gastric cancer are accumulated.",
keywords = "Cell line, Estrogen, Estrogens, Receptors, Stomach neoplasms",
author = "Kim, {Myung Jin} and Cho, {Sung Il} and Lee, {Kun Ok} and Han, {Hyung Joon} and Taejin Song and Seong-Heum Park",
year = "2013",
month = "10",
day = "10",
doi = "10.5230/jgc.2013.13.3.172",
language = "English",
volume = "13",
pages = "172--178",
journal = "Journal of Gastric Cancer",
issn = "2093-582X",
publisher = "Korean Gastric Cancer Association",
number = "3",

}

TY - JOUR

T1 - Effects of 17β-estradiol and estrogen receptor antagonists on the proliferation of gastric cancer cell lines

AU - Kim, Myung Jin

AU - Cho, Sung Il

AU - Lee, Kun Ok

AU - Han, Hyung Joon

AU - Song, Taejin

AU - Park, Seong-Heum

PY - 2013/10/10

Y1 - 2013/10/10

N2 - Purpose: The aims of this study were as follow: 1) to describe the expression status of estrogen receptor-α and-β mRNAs in five gastric carcinoma cell lines; 2) to evaluate in vitro the effects of 17β-estradiol and estrogen receptor antagonists on the proliferation of the cell lines. Materials and Methods: Detection of estrogen receptor-α and estrogen receptor-β mRNA in five human gastric cancer cell lines (AGS, KATO III, MKN28, MKN45 and MKN74) was made by the reverse transcription-polymerase chain reaction system. To evaluate the effect of 17β-estradiol and estrogen receptor antagonists on the proliferation of gastric cancer cell line, the cell lines which expressed both estrogen receptors were chosen and treated with 17β-estradiol and estrogen receptor antagonists (methyl-piperidino-pyrazole and pyrazolo [1,5-a] pyrimidine). Cell proliferation was assessed with the methylthiazol tetrazolium test. Results: Estrogen receptor-α and estrogen receptor-β mRNAs were expressed in three (KATO III, MKN28 and MKN45) and all of the five gastric cancer cell lines, respectively. At higher concentrations, 17β-estradiol inhibited cell growth of MKN28, MKN45 and KATO III cell lines. Neither estrogen receptor-α nor estrogen receptor-β antagonist blocked the anti-proliferative effect of 17β-estradiol. Conclusions: Our results indicate that estrogen receptor-β mRNAs are preferentially expressed in gastric cancers and also imply that hormone therapy rather than estrogen receptor blockers may be a useful strategy for the treatment of estrogen receptor-β positive gastric cancer. Its therapeutic significance in gastric cancer are, however, limited until more evidence of the roles of estrogen receptors in the gastric cancer are accumulated.

AB - Purpose: The aims of this study were as follow: 1) to describe the expression status of estrogen receptor-α and-β mRNAs in five gastric carcinoma cell lines; 2) to evaluate in vitro the effects of 17β-estradiol and estrogen receptor antagonists on the proliferation of the cell lines. Materials and Methods: Detection of estrogen receptor-α and estrogen receptor-β mRNA in five human gastric cancer cell lines (AGS, KATO III, MKN28, MKN45 and MKN74) was made by the reverse transcription-polymerase chain reaction system. To evaluate the effect of 17β-estradiol and estrogen receptor antagonists on the proliferation of gastric cancer cell line, the cell lines which expressed both estrogen receptors were chosen and treated with 17β-estradiol and estrogen receptor antagonists (methyl-piperidino-pyrazole and pyrazolo [1,5-a] pyrimidine). Cell proliferation was assessed with the methylthiazol tetrazolium test. Results: Estrogen receptor-α and estrogen receptor-β mRNAs were expressed in three (KATO III, MKN28 and MKN45) and all of the five gastric cancer cell lines, respectively. At higher concentrations, 17β-estradiol inhibited cell growth of MKN28, MKN45 and KATO III cell lines. Neither estrogen receptor-α nor estrogen receptor-β antagonist blocked the anti-proliferative effect of 17β-estradiol. Conclusions: Our results indicate that estrogen receptor-β mRNAs are preferentially expressed in gastric cancers and also imply that hormone therapy rather than estrogen receptor blockers may be a useful strategy for the treatment of estrogen receptor-β positive gastric cancer. Its therapeutic significance in gastric cancer are, however, limited until more evidence of the roles of estrogen receptors in the gastric cancer are accumulated.

KW - Cell line

KW - Estrogen

KW - Estrogens

KW - Receptors

KW - Stomach neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84885051124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885051124&partnerID=8YFLogxK

U2 - 10.5230/jgc.2013.13.3.172

DO - 10.5230/jgc.2013.13.3.172

M3 - Article

VL - 13

SP - 172

EP - 178

JO - Journal of Gastric Cancer

JF - Journal of Gastric Cancer

SN - 2093-582X

IS - 3

ER -